A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Biogen

Status and phase: Completed; Phase 1

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: BIIB022 With Paclitaxel and Carboplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00970580

212-LC-101

Details and patient eligibility

About

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >/= 18 years old
• Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
• ECOG Performance Status 0 or 1

Exclusion criteria

• History of another primary cancer within 3 years
• Any prior or concurrent investigational or standard therapy for treatment of NSCLC
• Prior anti-IGF-1R therapy
• Unstable diabetes

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

BIIB022 in Combination with Paclitaxel and Carboplatin

Experimental group

Description:

BIIB022 in Combination with Paclitaxel and Carboplatin

Treatment:

Drug: BIIB022 With Paclitaxel and Carboplatin